Analysis of Pathologic Complete Response Rates Between Different Neoadjuvant Radiation Treatment Regimens for Rectal Cancer

Placeholder Show Content

Abstract/Contents

Abstract
The standard of care for rectal cancer is long or short course radiation followed by surgery with or without adjuvant chemotherapy. Recently, total neoadjuvant therapy (TNT), an approach consisting of giving all chemotherapy and radiotherapy prior to definitive surgery, has been demonstrated to be a promising alternative. This study aims to assess the pathologic complete response (pCR) rates among different neoadjuvant treatment regimens and determine if neoadjuvant chemotherapy improves pCR rates. Electronic medical databases were queried to identify rectal cancer patients treated with neoadjuvant therapy at one institution from 2006-2019. Patients were grouped accordingly: long-course chemoradiation (CRT), long-course chemoradiation with chemotherapy (CRT TNT), short-course radiation (SCRT), and short-course radiation with chemotherapy (SCRT TNT). Patients without follow-up data or surgical pathology reports were excluded. pCR was defined as no evidence of disease at surgery. pCR rates were compared using descriptive statistics and Chi-square analysis. 249 patients were analyzed. There were 200 (80.3%) patients who received CRT, 26 (10.4%) who received CRT TNT, 13 (5.2%) patients who received SCRT, and 10 (4%) patients who received SCRT TNT. Initial stage was different between groups, with metastatic patients more likely to receive SCRT TNT (p<0.001). The median time to surgery were significantly different between groups (p<0.001). 11 (42.3%) and 6 (60%) patients received FOLFOX, and 13 (50%) and 4 (40%) of the patients received XELOX for CRT TNT and SCRT TNT, respectively. The remaining patients (7.7%) in the CRT TNT group received Capecitabine. For CRT, 53 (26.5%) patients achieved pCR, 3 (11.5%) in CRT TNT, 1 (7.7%) in SCRT, and 2 (20%) in SCRT TNT. None of these differences were statistically different (p=0.19). On univariate analysis, age (p=0.13), clinical T stage (p=0.13), clinical N stage (p=0.95), time to surgery (p=0.82), and presence of chemotherapy in the neoadjuvant regimen (p=0.22) were not significant predictors for pCR. Surprisingly, in this analysis, total neoadjuvant treatment for rectal cancer did not improve pCR rates over CRT or SCRT alone. Because of the relatively small numbers of patients in the TNT and SCRT groups, interpretation of these data should be considered preliminary. These data indicate that given the high pCR rates achievable with standard of care CRT, additional gains in pCR rates may require a more intensive TNT approach. Future studies are needed to further investigate this hypothesis prospectively.

Description

Type of resource text
Date created June 2021
Date modified December 5, 2022
Publication date May 4, 2022

Creators/Contributors

Author Koong, Amanda J.
Degree granting institution Stanford University, Department of Biology, 2021
Thesis advisor Le, Quynh
Thesis advisor Morrison, Ashby

Subjects

Subject Biology
Subject rectal cancer
Subject total neoadjuvant therapy
Genre Text
Genre Thesis

Bibliographic information

Access conditions

Use and reproduction
User agrees that, where applicable, content will not be used to identify or to otherwise infringe the privacy or confidentiality rights of individuals. Content distributed via the Stanford Digital Repository may be subject to additional license and use restrictions applied by the depositor.
License
This work is licensed under a Creative Commons Attribution Share Alike 3.0 Unported license (CC BY-SA).

Preferred citation

Preferred citation
Koong, Amanda J.; Le, Quynh; Morrison, Ashby. (2021). Analysis of Pathologic Complete Response Rates Between Different Neoadjuvant Radiation Treatment Regimens for Rectal Cancer. Stanford Digital Repository. Available at: https://purl.stanford.edu/rb091nr7015

Collection

Undergraduate Theses, Department of Biology, 2020-2021

View other items in this collection in SearchWorks

Contact information

Also listed in

Loading usage metrics...